Medical Tracking Solutions

medicaltracking.com

Medical Tracking Solutions, Inc. was established by an experienced team of industry professionals with expertise in the areas of medical device sales, distribution, logistics, loaner kit processing, and software development. The MTS team’s own intimate understanding of the medical industry's challenges and the critical need for solving the many problems associated with field inventory, multi-level bill of material tracking, and mobile inventory, is what prompted the development of MTS’s first product, iTraycer.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

ACULYS PHARMA AND SUSMED HAVE ENTERED INTO A CONTRACT TO CONDUCT THE WORLD'S FIRST CLINICAL TRIAL UTILIZING BLOCKCHAIN TECHNOLOGY

Aculys Pharma, Inc. | July 13, 2022

news image

Aculys Pharma, Inc. a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, has entered into a contract with SUSMED, Inc., a company that promotes digital medicine to conduct the world's first1 corporate-sponsored clinical trial using blockchain technology. The clinical trial utilizing this blockchain technology, provided by SUSMED, will be conducted in collaboration with CMIC Co., Ltd., a pioneer in drug development suppo...

Read More

INNOVATION PHARMACEUTICALS GRANTS INTELLECTUAL PROPERTY AND COMMERCIALIZATION RIGHTS TO FOX CHASE CHEMICAL DIVERSITY FOR ANTIFUNGAL TECHNOLOGY

Innovation Pharmaceuticals, Fox Chase Chemical Diversity Center | July 23, 2020

news image

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announces today that the Company and Fox Chase Chemical Diversity Center, Inc. have amended an earlier collaborative research agreement related to antifungal drug discovery work. Under the amended terms, and in exchange for a six (6) percent fee tied to all potential future proceeds—including upfront payments, milestone payments and royalties—the Company is granting FCCDC all discovery, intellectua...

Read More

PHARMACY MARKET

INDIVIOR ENTERS AN EXCLUSIVE LICENSING AGREEMENT WITH ALAR PHARMACEUTICALS

PR Newswire | October 12, 2023

news image

Indivior PLC a leading addiction treatment company, announced that it has gained exclusive global rights to develop, manufacture, and commercialize Alar Pharmaceuticals Inc.'s ("Alar") portfolio of long-acting injectable formulations that release a prodrug1 of buprenorphine at varying durations, including its lead long-acting injectable ("LAI") candidate, ALA-1000. <...

Read More

Business Insights, PHARMACY MARKET

ANNOGEN ANNOUNCES RESEARCH PROJECT WITH PFIZER TO TEST NON-CODING GENETIC SEQUENCES

Annogen | December 14, 2022

news image

Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, today announced it has begun a research project with Pfizer to functionally test tens of thousands of disease-related non-coding sequence variants for their effect on gene regulation. The results may contribute to drug discovery by identifying functionally relevant non-coding variants that play a central role in diseases. More than 95 p...

Read More
news image

Business Insights

ACULYS PHARMA AND SUSMED HAVE ENTERED INTO A CONTRACT TO CONDUCT THE WORLD'S FIRST CLINICAL TRIAL UTILIZING BLOCKCHAIN TECHNOLOGY

Aculys Pharma, Inc. | July 13, 2022

Aculys Pharma, Inc. a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, has entered into a contract with SUSMED, Inc., a company that promotes digital medicine to conduct the world's first1 corporate-sponsored clinical trial using blockchain technology. The clinical trial utilizing this blockchain technology, provided by SUSMED, will be conducted in collaboration with CMIC Co., Ltd., a pioneer in drug development suppo...

Read More
news image

INNOVATION PHARMACEUTICALS GRANTS INTELLECTUAL PROPERTY AND COMMERCIALIZATION RIGHTS TO FOX CHASE CHEMICAL DIVERSITY FOR ANTIFUNGAL TECHNOLOGY

Innovation Pharmaceuticals, Fox Chase Chemical Diversity Center | July 23, 2020

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announces today that the Company and Fox Chase Chemical Diversity Center, Inc. have amended an earlier collaborative research agreement related to antifungal drug discovery work. Under the amended terms, and in exchange for a six (6) percent fee tied to all potential future proceeds—including upfront payments, milestone payments and royalties—the Company is granting FCCDC all discovery, intellectua...

Read More
news image

PHARMACY MARKET

INDIVIOR ENTERS AN EXCLUSIVE LICENSING AGREEMENT WITH ALAR PHARMACEUTICALS

PR Newswire | October 12, 2023

Indivior PLC a leading addiction treatment company, announced that it has gained exclusive global rights to develop, manufacture, and commercialize Alar Pharmaceuticals Inc.'s ("Alar") portfolio of long-acting injectable formulations that release a prodrug1 of buprenorphine at varying durations, including its lead long-acting injectable ("LAI") candidate, ALA-1000. <...

Read More
news image

Business Insights, PHARMACY MARKET

ANNOGEN ANNOUNCES RESEARCH PROJECT WITH PFIZER TO TEST NON-CODING GENETIC SEQUENCES

Annogen | December 14, 2022

Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, today announced it has begun a research project with Pfizer to functionally test tens of thousands of disease-related non-coding sequence variants for their effect on gene regulation. The results may contribute to drug discovery by identifying functionally relevant non-coding variants that play a central role in diseases. More than 95 p...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us